P21 dosage and evidence

What is P21?

How does P21 work?

It copies CNTF's signal. That helps new brain cells form in the memory center, the hippocampus, and helps connections between brain cells adapt.

What have studies in people found about P21?

No person has ever been given P21. There is no registered trial, no published study in people of any kind, and no data on how the body handles it or how safe it is. Everything known comes from rats, mice and cells, mostly from one research group, over more than ten years.

• No registered trials. ClinicalTrials.gov lists no study of P021 or P21, at any stage, in any country, at any point since the first rat and mouse papers in 2013.
• No papers in people. PubMed's 17 records for P021 are all rat and mouse studies or cells in a dish.
• In old rats: P021 by mouth over a long period, in rats 22 to 24 months old, slowed the usual drop in learning and memory with age. It also protected the growth of new brain cells, raised BDNF (a brain growth signal), restored markers of healthy nerve connections, and lowered a brain chemical seen on scans. Rats.
• In mice bred to get Alzheimer's-like disease: 12 months of P021 by mouth cut the build-up of two hallmark proteins of the disease, tangled tau and loose amyloid. Mice.
• In the same mice, started early at 3 months old: P021 prevented the amyloid and tau build-up and the brain damage that goes with it, and rescued memory of events. Mice.
• Still in mice in 2026: a brain scan study published in June 2026, and corrected in July, found changes in fine brain structure after early P021 in the same mouse. Thirteen years after the first rodent papers, the newest work is still in the same mouse.
• A second lab tested it in a different disease, also in animals: a 2024 study in the Journal of Neurodevelopmental Disorders used cells and mice to model CDKL5 deficiency disorder, a rare childhood brain disorder. Independent work, and still not in people.

What this does not tell you: There is no dose, no route, no half-life, no blood level, no safety record and no result in a person. The rodent work gave it by mouth over long periods, which is unusual and to the credit of the team that did it. But a compound that helps an old rat's memory has cleared none of the steps between that and a person. New brain cell growth and BDNF are signs of how something might work, not proof of better thinking. Nothing here tells you what P21 would do to a human brain, or whether it even gets there.

What do people who took P21 report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Reports describe it as subtle and building over time rather than sudden, needing several days of consecutive use before anyone claims to notice anything, which is a contrast people draw explicitly against the peptides that are felt within an hour.
• What people report is learning and retention, particularly for procedural material, along with reduced stress and improved sleep. These are a small number of accounts from a small number of people, and the same names recur.
• Route is a live argument. Injection is described by those who do it as straightforward, and the preference for the nasal route is attributed in the threads to needle aversion rather than to any advantage. People specifically warn that going up the nose is not the safer option and raise nasal membrane damage, drawing on reports about related peptides.
• Product authenticity is the most concrete negative in the discussion. A claim circulates that material sold by at least one named vendor was not even the correct sequence, and it is repeated by people warning others off that source.
• Almost nobody posts a negative experience log, and almost nobody posts a no-effect report either. In a compound with this little use, that reflects how few people have tried it rather than telling you anything about the compound, and the enthusiasm on display comes from a handful of people who were enthusiastic before they started.
• Stacking is the norm, most often with other experimental brain peptides, so essentially no account isolates it.

Sources: Brain Health and Retailer discussion threads on LongeCity covering P21 and its combinations, found by site-restricted search, September 2026. This is a thin body of discussion by a small group and the entry is short for that reason. Nothing above is attributed to any specific post and no post is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Animal study2014
  Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound

  In old rats, 22 to 24 months of age, P021 by mouth over a long time slowed memory loss, brought back new brain cell growth and raised BDNF, a brain growth signal.

  Chronic oral P021 reduced age-related learning and memory decline in 22 to 24-month-old rats, restored neurogenesis and raised BDNF expression.

  PMID 24702821 Neurobiology of Aging
• Animal study2014
  Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease

  In mice bred to get Alzheimer-like disease, 12 months of P021 cut tangled tau and loose amyloid-beta, probably by raising BDNF.

  12 months of P021 in 3xTg-AD mice reduced tau hyperphosphorylation and soluble amyloid-beta, likely via increased BDNF.

  PMID 25046994 Neurobiology of Disease
• Animal study2017
  Prevention of amyloid-beta and tau pathologies, associated neurodegeneration, and cognitive deficit by early treatment with a neurotrophic compound

  In mice bred to get Alzheimer-like disease, P021 started at 3 months of age prevented brain cell loss and the build-up of amyloid and tau. It also saved their memory for events.

  P021 started at 3 months in 3xTg-AD mice prevented neurodegeneration and amyloid and tau pathology and rescued episodic memory.

  PMID 28387677 Journal of Alzheimer's Disease
• Animal study2026
  Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease

  In mice, still. Thirteen years after the first reports, the newest study of P21 is in mice bred to develop Alzheimer's-like disease. This one used brain scans to spot changes in fine brain structure after early treatment. It was published in June 2026 and corrected the next month. No human has ever been given this compound, and no trial in people has been registered.

  The most recent P021 study, published June 2026 and corrected in July 2026, is still in the 3xTg-AD mouse. Thirteen years after the first rodent reports, no step toward a human study has been taken.

  PMID 41740658 Magnetic Resonance Imaging
• Animal study2024
  Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder

  In cells and mice. A second lab picked the compound up, and still nobody gave it to a person. This group tested the same peptide in cells and in mice bred to model a childhood brain disorder. Independent work counts for something, because it means the results do not rest on one team alone. It is still animal work. Nothing here tells you what the compound does in a human.

  A second research group tested the CNTF peptide mimetic in a different disorder, in cells and in mice. Independent work, and still no human participant.

  PMID 39592934 Journal of Neurodevelopmental Disorders